0000880771-17-000120.txt : 20170703 0000880771-17-000120.hdr.sgml : 20170703 20170703160217 ACCESSION NUMBER: 0000880771-17-000120 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170703 DATE AS OF CHANGE: 20170703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blobel Friedhelm CENTRAL INDEX KEY: 0001363213 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 17945454 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2017-06-30 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001363213 Blobel Friedhelm 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 1 0 0 President & CEO Common Stock 2017-06-30 4 M 0 27654 3.55 A 149863 D Common Stock 2017-06-30 4 S 0 27654 11 D 122209 D Common Stock 2017-06-30 4 M 0 7390 5.13 A 129599 D Common Stock 2017-06-30 4 S 0 7390 11 D 122209 D Non-Qualified Stock Option (right to buy) 3.55 2017-06-30 4 M 0 27654 0 D 2020-03-05 Common Stock 27654 0 D Non-Qualified Stock Option (right to buy) 5.13 2017-06-30 4 M 0 7390 0 D 2021-05-12 Common Stock 7390 142610 D The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016. Granted under the Issuer's 2005 Equity Incentive Plan. 25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer. 25% of such shares vest April 5, 2012 and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer. /s/ Friedhelm Blobel, Ph.D. 2017-07-03